Is immunotherapy here to stay in multiple myeloma?

Is immunotherapy here to stay in multiple myeloma?

Immune escape and impaired immune surveillance have been identified as emerging hallmarks of cancer.1 Multiple myeloma represents a genuine example of disrupted immune surveillance characterized by: impaired antibody production, deregulation of the T and natural killer cell compartment, disruption of antigen presentation machinery, upregulation of inhibitory surface ligands, and recruitment of ...

hpv is here to stay.

Immunotherapy in Multiple Myeloma

The treatment of multiple myeloma has evolved significantly over the past decades, spanning from alkylator-based therapy to the more recent novel therapies that include proteasome inhibition and immunomodulatory agents. The introduction of immunotherapy to the treatment landscape of multiple myeloma has led to the development of new strategies and therapies that engage the immune system to enha...

Immunotherapy for Multiple Myeloma

1Clinic for Stem Cell Transplantation, Center of Oncology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany 2 Service d’Hématologie Clinique, Hôpital Hôtel-Dieu, CHU de Nantes, Place Alexis Ricordeau, 44093 Nantes Cedex, France 3Hematology and Bone Marrow Transplantation, Internal Medicine, Chaim Sheba Medical Center, 52621 Tel-Hashomer, Israel 4Department o...

Is rotational atherectomy here to stay?

Rotational atherectomy was developed to ablate selectively inelastic atherosclerotic plaque, while deflecting normal arterial wall away from the rotating burr. Intravascular ultrasound (IVUS) studies have confirmed that rotablation differentially removes even hard, calcified plaque without damaging normal arterial wall. Early in clinical experience, the ability to ablate previously undilatable ...